Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.42 |
| ▸ | VEGFA | P15692 | 3/20 | 0.41 |
| ▸ | FLT1 | P17948 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.39 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752845 | 0.89 | EGLN3 (0.42) | EGLN3HPGDHSD17B10EGLN1VEGFA | |
| SCHEMBL3396710 | 0.86 | EGLN3 (0.71) | EGLN3EGLN1VEGFAFLT1FTO | |
| SCHEMBL3758199 | 0.85 | EGLN3 (0.39) | EGLN3HPGDHSD17B10EGLN1VEGFA | |
| SCHEMBL3518821 | 0.84 | EGLN3 (0.49) | EGLN3HPGDHSD17B10ALDH1A1LMNA | |
| SCHEMBL3524259 | 0.82 | EGLN3 (0.52) | EGLN3HPGDHSD17B10ALDH1A1LMNA | |
| SCHEMBL3762383 | 0.82 | EGLN3 (0.57) | EGLN3HPGDHSD17B10EGLN1VEGFA | |
| SCHEMBL3754317 | 0.79 | EGLN3 (0.55) | EGLN3EGLN1VEGFAFLT1FTO | |
| SCHEMBL3524105 | 0.77 | LMNA (0.49) | EGLN3HPGDHSD17B10ALDH1A1LMNA | |
| SCHEMBL3520006 | 0.76 | EGLN3 (0.43) | EGLN3HPGDHSD17B10EGLN1VEGFA | |
| SCHEMBL3756004 | 0.76 | EGLN3 (0.42) | EGLN3HPGDHSD17B10ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101932324-A | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC | 2010-12-29 | — | — | CN | disclosed |
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885HPGD 58/4885HSD17B10 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.